Trial reportAmerican journal of clinical dermatology2020
Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study.
Trial report in American journal of clinical dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Double Blind Placebo Controlled Pilot Study on Botulinum Toxin B as Treatment for Hidradenitis Suppurativa
Targeting Nociceptors in Hidradenitis Suppurativa
Botulinum Toxin-A for Hidradenitis Suppurativa
Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Guideline
- Demographic Gaps and Requirements for Participation: A Systematic Review of Clinical Trial Designs in Hidradenitis Suppurativa.Dermatology (Basel, Switzerland) · 2023Pooled it
- Pooled it
- Intrinsic Dysregulation and Environmental Modifiers in Hidradenitis Suppurativa: Toward an Integrated Pathophysiologic Model.Journal of clinical medicine · 2026Review
- A Narrative Review of Local Therapies in Hidradenitis Suppurativa: Treatment Landscape and Current Issues.Dermatology and therapy · 2026Review
- [Botulinum toxin preparations in dermatology : Characterization, comparison, and treatment options].Dermatologie (Heidelberg, Germany) · 2026Review
- Management of Hidradenitis Suppurativa in the United Arab Emirates (UAE): A Consensus Statement from the Emirates Dermatology Society.Dermatology and therapy · 2026Review
- Clostridium botulinum serotype B: microbial genetics, toxin biosynthesis, current applications, and future prospects.Archives of microbiology · 2025Review
- Treatment Strategies in Neutrophilic Dermatoses: A Comprehensive Review.International journal of molecular sciences · 2023Review
- Hidradenitis suppurativa - biologic therapy and other available treatment options.Postepy dermatologii i alergologii · 2023Review
- Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa-Part II: Procedural and Wound Care Therapies.Dermatology and therapy · 2023Review
- The Current Clinical Trial Landscape for Hidradenitis Suppurativa: A Narrative Review.Dermatology and therapy · 2023Review
- Evaluating the Impact of Exclusion Criteria on the Generalizability of Hidradenitis Suppurativa Treatment Research.JID innovations : skin science from molecules to population health · 2023Article
- Hidradenitis Suppurativa: The Influence of Gender, the Importance of Trigger Factors and the Implications for Patient Habits.Biomedicines · 2022Review
- The Use of Botulinum Toxin in the Management of Hidradenitis Suppurativa: A Systematic Review.Plastic and reconstructive surgery. Global open · 2022Article
- Hidradenitis Suppurativa: Absence of Hyperhidrosis but Presence of a Proinflammatory Signature in Patients' Sweat.Acta dermato-venereologica · 2022Article
- Article
- Biologics and Small Molecule Inhibitors for Treating Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis.Biomedicines · 2022Review
- Off-Label Use of Botulinum Toxin in Dermatology-Current State of the Art.Molecules (Basel, Switzerland) · 2022Review
- Trends in Hidradenitis Suppurativa Disease Severity and Quality of Life Outcome Measures: Scoping Review.JMIR dermatology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBotulinum toxin (BTX) is a potent neurotoxin with a long history of therapeutic application in neurological and dermatological conditions, with a strong efficacy and safety profile.
objectiveOur aim was to assess whether intradermal injection with BTX-B is an effective treatment for hidradenitis suppurativa (HS).
methodsTwenty patients with HS stage I-III disease, according to Hurley's classification, were consecutively included for treatment with either a placebo or BTX-B. At the next intervention after 3 months, all participants received the active substance and another follow-up at 6 months. The primary outcome was quality of life, measured using the Dermatology Life Quality Index (DLQI), while secondary outcomes were the visual analogue scale (VAS) for pain in the worst boil and HS-related impairment of general health (VAS), as well as changes in physician-reported disease activity assessed as the number of total lesions, and reported adverse effects of treatment.
resultsThe DLQI improved from a median of 17 at baseline to 8 at 3 months in the BTX-B group, compared with a reduction from 13.5 to 11 in the placebo group (p <0.05). Improvement of the patients' own ratings of symptoms and a reduction in total lesions supplemented the primary outcome. Fifty-five percent of the study population reported some degree of hyperhidrosis.
conclusionBTX-B improves the quality of life in patients with HS. Furthermore, comorbidity between HS and hyperhidrosis is suggested.
trial registrationClinicalTrials.gov identifier: NCT03103074.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.